Print Page      Close Window     

SEC Filings

10-Q
ATHENEX, INC. filed this Form 10-Q on 05/09/2019
Entire Document
 

 

Global Supply Chain Platform—This operating segment includes APS and Polymed. APS is a contract manufacturing company that provides small to mid-scale Current Good Manufacturing Practices (“cGMP”) manufacturing of clinical and commercial products for pharmaceutical and biotech companies and for the internal supplies to the clinical studies and commercial development of our proprietary drugs. APS also performs microbiological and analytical testing for raw material and formulated products and has expanded and begun to manufacture and sell pharmaceutical products under Section 503B of the Compounding Quality Act within the Federal Food, Drug & Cosmetic Act. Polymed markets and sells active pharmaceutical ingredient (“API”) and medical devices in North America, Europe, and Asia from its locations in Texas and China. Polymed also develops new compounds and processing techniques, and manufactures API at Taihao, a cGMP facility in Chongqing, China.

Commercial Platform—This operating segment includes Athenex Pharmaceutical Division, which focuses on the manufacturing, distribution, and sales of specialty pharmaceuticals. This segment provides services and products to external customers based mainly in the United States.

The Company’s Oncology Innovation Platform segment operates and holds long-lived assets located in the United States, Taiwan, Hong Kong, and mainland China. The Global Supply Chain Platform segment operates and holds long-lived assets located in the United States and China. The Commercial Platform segment operates and holds long-lived assets located in the United States. For geographic segment reporting, product sales have been attributed to countries based on the location of the customer.

Segment information is as follows (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

2019

 

 

2018

 

Total revenue:

 

 

 

 

 

 

 

 

Oncology Innovation Platform

 

$

144

 

 

$

25,231

 

Global Supply Chain Platform

 

 

11,339

 

 

 

5,127

 

Commercial Platform

 

 

14,675

 

 

 

8,694

 

Total revenue for reportable segments

 

 

26,158

 

 

 

39,052

 

Intersegment revenue

 

 

(851

)

 

 

(1,216

)

Total consolidated revenue

 

$

25,307

 

 

$

37,836

 

 

Intersegment revenue eliminated in the above table reflects sales from the Global Supply Chain Platform to the Oncology Innovation Platform.

 

 

 

Three Months Ended March 31,

 

 

 

2019

 

 

2018

 

Total revenue by product group:

 

 

 

 

 

 

 

 

API sales

 

$

4,831

 

 

$

2,642

 

Medical device sales

 

 

 

 

 

585

 

Contract manufacturing revenue

 

 

251

 

 

 

241

 

Commercial product sales

 

 

20,081

 

 

 

9,137

 

License fees

 

 

 

 

 

25,091

 

Consulting revenue

 

 

105

 

 

 

 

Grant revenue

 

 

39

 

 

 

140

 

Total consolidated revenue

 

$

25,307

 

 

$

37,836

 

 

Intersegment revenue is recorded by the selling segment when it is realized or realizable and all revenue recognition criteria are met. Upon consolidation, all intersegment revenue and related cost of sales are eliminated from the selling segment’s ledger.

 

 

 

Three Months Ended March 31,

 

 

 

2019

 

 

2018

 

Net (loss) income attributable to Athenex, Inc.:

 

 

 

 

 

 

 

 

Oncology Innovation Platform

 

$

(27,603

)

 

$

1,509

 

Global Supply Chain Platform

 

 

(767

)

 

 

(6,569

)

Commercial Platform

 

 

(6,863

)

 

 

(2,238

)

Total consolidated net loss attributable to Athenex, Inc.

 

$

(35,233

)

 

$

(7,298

)

16